黑人与白人2型糖尿病患者慢性肾脏病发病率与进展差异
该研究对ACCORD试验中1937名黑人和6372名白人2型糖尿病参与者进行事后分析,随访中位4.4-4.7年。结果显示黑人参与者发生CKD的风险显著低于白人(HR 0.73),而eGFR下降、微量白蛋白尿、大量白蛋白尿及肾衰竭风险无种族差异。
要点
- 黑人2型糖尿病患者发生CKD的风险较白人低27%。
- eGFR下降速率及白蛋白尿风险无种族差异。
- 肾衰竭或血肌酐>3.3 mg/dl风险无种族差异。
核心结论
- 在ACCORD试验参与者中,黑人2型糖尿病患者的CKD发病率低于白人,但eGFR下降、白蛋白尿及肾衰竭风险无种族差异。
研究设计与样本
- ACCORD试验的事后分析,纳入1937名黑人和6372名白人2型糖尿病参与者,随访中位4.4-4.7年。
主要发现
- 黑人参与者CKD发病率为21/1000人年,白人参与者为28/1000人年,黑人风险显著更低(HR 0.73;95%CI 0.57-0.92)。
- 微量白蛋白尿发生率黑人58/1000人年 vs 白人55/1000人年,无显著差异。
- 大量白蛋白尿发生率黑人16/1000人年 vs 白人14/1000人年,无显著差异。
- 肾衰竭或血肌酐>3.3 mg/dl发生率黑人7/1000人年 vs 白人6/1000人年,无显著差异。
关键数值与推荐
- CKD定义为eGFR<60 ml/min/1.73m2且较基线下降≥25%且eGFR斜率<-1.6 ml/min/1.73m2/年。
- 肾衰竭或血肌酐>3.3 mg/dl为肾脏结局指标。
临床怎么用
- 黑人2型糖尿病患者CKD风险较低,但eGFR下降及白蛋白尿风险与白人相似,需个体化监测。
局限性
- 为事后分析,可能存在残余混杂,结果需在更广泛人群中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Type 2 diabetes and associated CKD disproportionately affect blacks. It is uncertain if racial disparities in type 2 diabetes-associated CKD are driven by biologic factors that influence propensity to CKD or by differences in type 2 diabetes care. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a post hoc analysis of 1937 black and 6372 white participants of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial to examine associations of black race with change in eGFR and risks of developing microalbuminuria, macroalbuminuria, incident CKD (eGFR<60 ml/min per 1.73m2, ≥25% decrease from baseline eGFR, and eGFR slope <-1.6 ml/min per 1.73 m2 per year), and kidney failure or serum creatinine >3.3 mg/dl. RESULTS: During a median follow-up that ranged between 4.4 and 4.7 years, 278 black participants (58 per 1000 person-years) and 981 white participants (55 per 1000 person-years) developed microalbuminuria, 122 black participants (16 per 1000 person-years) and 374 white participants (14 per 1000 person-years) developed macroalbuminuria, 111 black participants (21 per 1000 person-years) and 499 white participants (28 per 1000 person-years) developed incident CKD, and 59 black participants (seven per 1000 person-years) and 178 white participants (six per 1000 person-years) developed kidney failure or serum creatinine >3.3 mg/dl. Compared with white participants, black participants had lower risks of incident CKD (hazard ratio, 0.73; 95% confidence intervals, 0.57 to 0.92). There were no significant differences by race in eGFR decline or in risks of microalbuminuria, macroalbuminuria, and kidney failure or of serum creatinine >3.3 mg/dl. CONCLUSIONS: Black participants enrolled in a randomized controlled trial had lower rates of incident CKD compared with white participants. Rates of eGFR decline, microalbuminuria, macroalbuminuria, and kidney failure did not vary by race.
引用
- Gerber C, Cai X, Lee J, et al. Incidence and Progression of Chronic Kidney Disease in Black and White Individuals with Type 2 Diabetes. Clin J Am Soc Nephrol. 2018. PMID: 29798889. doi:10.2215/CJN.11871017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。